反应详情

A solution of N-[5-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidine-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1,3-thiazol-2-yl]acetamide (75 mg, 0.15 mmol) in 6 N hydrochloric acid (4 mL) was stirred at 95° C. for 15 h. After cooling to room temperature the mixture was neutralized with 50% aqueous sodium hydroxide, concentrated to dryness, and the solid residue extracted with ethanol (3×10 mL). Evaporation of the solvent and purification of the residue by preparative HPLC afforded 5-(4-{5-[(4-fluorophenyl)methyl]-6-methylpyrimidin-4-yl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1,3-thiazol-2-amine (43 mg, 62% yield) as a colorless solid. 1H NMR (400 MHz, CD3OD): 8.46 (s, 1H), 7.21 (m, 1H), 7.11 (m, 4H), 6.98 (s, 1H), 6.90 (d, 1H), 6.61 (m, 1H), 4.46 (s, 2H), 4.26 (ms, 2H), 3.97 (s, 2H), 3.87 (m, 2H), 2.21 (s, 3H); MS (EI) C24H22FN5OS: 448 (MH+).

1. concentrationconcentrated to dryness
2. extractionthe solid residue extracted with ethanol (3×10 mL)
3. customEvaporation of the solvent and purification of the residue by preparative HPLC